MEI Pharma phase 1b lymphoma trial gets 83% overall response rate

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announced that updated data presented in an oral presentation at ICML 2019 from a Phase 1b study of investigational ME-401, a selective oral inhibitor of PI3K delta, demonstrate an 83% overall response rate in patients with relapsed or refractory (r/r) follicular lymphoma (FL) and r/r chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

Additionally, the data demonstrate:

• Overall response rates of 75% to 100% across all patient groups receiving ME-401.
  • 100% overall response rate in all patients with CLL/SLL.
• A lower rate of delayed, grade 3 adverse events observed in patients dosed on the intermittent schedule (IS) (e.g. 9.7% diarrhea/colitis for IS dosing).
• Durable responses in patients with FL and CLL/SLL across both CS and IS dosing groups.
  • Median PFS not reached.

The ME-401 ICML 2019 presentation can be accessed on the MEI Pharma website.

https://www.prnewswire.com/news-releases/mei-pharma-presents-updated-clinical-data-from-the-me-401-phase-1b-study-in-patients-with-indolent-b-cell-malignancies-at-the-2019-international-conference-on-malignant-lymphoma-icml-300872982.html